FindTrial
Sign In

Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal Tract

Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal Tract: A Prospective, Multi-Center, Single-Arm, Open-Label, Pilot Clinical Trial

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06939907
Enrollment
60
Registered
2025-04-23
Start date
2025-06-30
Completion date
2027-07-31
Last updated
2025-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diverticular Bleeding, Lower Gastrointestinal Bleeding

Brief summary

Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal Tract

Interventions

DEVICENexpowder™

Nexpowder™ hemostatic powder

Sponsors

Next Biomedical Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults aged 19 years or older at the time of screening * Patients diagnosed with diverticular bleeding

Exclusion criteria

* Patients diagnosed with upper gastrointestinal bleeding

Design outcomes

Primary

MeasureTime frameDescription
Rebleeding rate30 days post treatment30 days after successful endoscopic hemostasis

Secondary

MeasureTime frameDescription
Hemostasis rateImmediately after the procedureHemostasis rate
Rebleeding rate7 days post treatmentRebleeding rate

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026